Eccogene
PrivateLast Round
Strategic
Nov 9, 2023
Est. Valuation
$498M
Total Funding Raised
$238.8M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Eccogene is a clinical-stage biopharmaceutical company that develops next-generation oral small molecule therapeutics for chronic cardiometabolic and inflammatory conditions.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Eccogene Comparables
Compare Eccogene with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Regor Therapeutics Group | 86% | |
| Kailera Therapeutics | 84% | |
| Structure Therapeutics | 84% |
Eccogene Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Strategic | Nov 9, 2023 | ||||
| Series B | Jun 11, 2023 | ||||
| Series A Extension | Dec 22, 2020 | ||||
| Series A | Sep 7, 2018 |
Eccogene Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| New Alliance Capital | Series B |
| TF Capital | Series A |
| 健壹资本 | Series A |
| Huajin Capital | Series B |
| Huagai Capital | Series A Extension |
| Qingsong Capital | Series B, Series A Extension |
| Oriza Seed Venture Capital | Series B, Series A Extension |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 25, 2026
Monthly visitors grew 52% MoM.
- Apr 8, 2026
Job posting indicates company is pre-IPO.
Recent news
Latest coverage and updates
- is_developingJul 10, 2026
Eccogene, Inc. is developing GLP-1-based drugs to treat obesity and diabetes.
Eccogene Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Eccogene's valuation, stock price, and market status.
Is Eccogene a public or private company?
Eccogene is a private company.
What is the current stock price of Eccogene?
Eccogene is a private company with no public stock price. No recent secondary market data is available.
How much is Eccogene worth (valuation)?
Valuation information for Eccogene is not publicly available.
Can I buy Eccogene stock?
Eccogene shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Eccogene's last funding round?
Eccogene's most recent funding round was Strategic on November 9, 2023.
Who are the main investors in Eccogene?
Key investors in Eccogene include New Alliance Capital, 健壹资本.
Will Eccogene IPO soon?
No public IPO plans have been announced for Eccogene.
How can I track Eccogene secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Eccogene's secondary market activity and sign up for updates.